BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Recio-Boiles A, Veeravelli S, Vondrak J, Babiker HM, Scott AJ, Shroff RT, Patel H, Elquza E, McBride A. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. World J Gastrointest Oncol 2019; 11(10): 866-876 [PMID: 31662825 DOI: 10.4251/wjgo.v11.i10.866]
URL: https://www.wjgnet.com/1948-5204/full/v11/i10/866.htm
Number Citing Articles
1
Tarinee Rungjirajittranon, Weerapat Owattanapanich, Yingyong Chinthammitr, Theera Ruchutrakool, Bundarika Suwanawiboon. Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysisThrombosis Journal 2022; 20(1) doi: 10.1186/s12959-022-00399-7
2
Shinji Rho, Chris Wang, Seyed Hamed Hosseini Dehkordi, James J. Sears, Z. Ian Hu. Bleeding and thrombotic events in bevacizumab-treated patients with colorectal cancer on novel oral anticoagulants and antiplatelet medicationsAmerican Heart Journal Plus: Cardiology Research and Practice 2023; 27: 100283 doi: 10.1016/j.ahjo.2023.100283
3
Maryam R. Hussain, Faisal S. Ali, Dhiran Verghese, Phyo Thazin Myint, Mubashir Ahmed, Zimu Gong, Yasmin Gerais, Mahrukh Siddiqui, Jenny J. Lin, Kevin Troy. Factor Xa inhibitors versus low molecular weight heparin for the treatment of cancer associated venous thromboembolism; A meta-analysis of randomized controlled trials and non-randomized studiesCritical Reviews in Oncology/Hematology 2022; 169: 103526 doi: 10.1016/j.critrevonc.2021.103526
4
Victoria R Nachar, Allison J Schepers. Clinical controversies in the treatment of cancer-associated venous thromboembolismJournal of Oncology Pharmacy Practice 2021; 27(4): 939 doi: 10.1177/1078155220984371
5
Damon E. Houghton, Danielle T. Vlazny, Ana I. Casanegra, Nichole Brunton, David A. Froehling, Ryan A. Meverden, David O. Hodge, Lisa G. Peterson, Robert D. McBane, Waldemar E. Wysokinski. Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous ThromboembolismMayo Clinic Proceedings 2021; 96(11): 2793 doi: 10.1016/j.mayocp.2021.04.026
6
William J. Chapin, Preeti Sudheendra, Luis Goity, Deepak Sudheendra. Epidemiology, Prevention, Diagnosis, and Management of Venous Thromboembolism in Gastrointestinal CancersDigestive Disease Interventions 2020; 4(03): 248 doi: 10.1055/s-0040-1716738
7
Phillip C. Nguyen, Hannah Stevens, Karlheinz Peter, James D. McFadyen. Submassive Pulmonary Embolism: Current Perspectives and Future DirectionsJournal of Clinical Medicine 2021; 10(15): 3383 doi: 10.3390/jcm10153383
8
Tirath Patel, Taha Nadeem, Usman Shahbaz, Fatima Tanveer, Muneeb Ahsan, Usman Saeed, Abdullah Ahmed, Vinesh Kumar, Syed M Ibne Ali Jaffari, Mohammad U Zaman, Satesh Kumar, Mahima Khatri, Giustino Varrassi, Prasanthi Vanga. Comparative Efficacy of Direct Oral Anticoagulants and Low-Molecular-Weight Heparin in Cancer-Associated Thromboembolism: A Systematic Review and Meta-AnalysisCureus 2023;  doi: 10.7759/cureus.41071
9
Mercedes Salgado, Elena Brozos-Vázquez, Begoña Campos, Paula González-Villarroel, María Eva Pérez, María Lidia Vázquez-Tuñas, David Arias. Venous Thromboembolism In Cancer Patients: “From Evidence to Care”Clinical and Applied Thrombosis/Hemostasis 2022; 28: 107602962210987 doi: 10.1177/10760296221098717
10
Maryam F Baloch, Adedimeji V Adepoju, Vaibhavkumar Falki, Mohsin Hajjaj, Tatiana Habet, Karina Habet, Amtul Mahrosh, Sumana Kundu, Janvi Kataria, Midhun Mathew, Tugba Saka, Mohammed Al-Tawil. Comparative Efficacy of Oral Apixaban and Subcutaneous Low Molecular Weight Heparins in the Treatment of Cancer-Associated Thromboembolism: A Meta-AnalysisCureus 2023;  doi: 10.7759/cureus.43447
11
Seohyun (Claudia) Choi, Jessica Wilczynski, Danielle Tompkins, Jimmy Gonzalez. A Worldwide Yearly Survey of New Data in Adverse Drug ReactionsSide Effects of Drugs Annual 2020; 42: 337 doi: 10.1016/bs.seda.2020.08.011